Novel potent and VEGFR-sparing TKIs (pralsetinib and selpercatinib) have been identified and demonstrated substantial clinical efficacy in RET-driven cancers; both have been approved as RET-targeted cancer drugs38–43. Here, RET is linked to cancer.